Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Massimo Gentile; Tait D. Shanafelt; Francesca Romana Mauro; Gianluigi Reda; Davide Rossi; Luca Laurenti; Maria Ilaria Del Principe; Giovanna Cutrona; Ilaria Angeletti; Marta Coscia; Yair Herishanu; Annalisa Chiarenza; Stefano Molica; Stefania Ciolli; Neta Goldschmidt; Francesco Angrilli; Annamaria Giordano; Angela Rago; Osnat Bairey; Giovanni Tripepi; Kari G. Chaffee; Parikh A. Sameer; Ernesto Vigna; Katja Zirlik; Lev Shvidel; Idanna Innocenti; Anna Grazia Recchia; Francesco Di Raimondo; Giovanni Del Poeta; Agostino Cortelezzi; Antonino Neri; Manlio Ferrarini; Gianluca Gaidano; Neil E. Kay; Aaron Polliack; Robin Foà; Fortunato Morabito

doi:10.1111/ejh.13149

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni TripepiKari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Abstract

An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.

Lingua originale	Inglese
pagine (da-a)	703-706
Numero di pagine	4
Rivista	European Journal of Haematology
Volume	101
Numero di pubblicazione	5
DOI	https://doi.org/10.1111/ejh.13149
Stato di pubblicazione	Pubblicato - nov 2018

Accesso al documento

10.1111/ejh.13149

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Gentile, M., Shanafelt, T. D., Mauro, F. R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M. I., Cutrona, G., Angeletti, I., Coscia, M., Herishanu, Y., Chiarenza, A., Molica, S., Ciolli, S., Goldschmidt, N., Angrilli, F., Giordano, A., Rago, A., Bairey, O., ... Morabito, F. (2018). Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. European Journal of Haematology, 101(5), 703-706. https://doi.org/10.1111/ejh.13149

@article{f9d919de79614cc09852fb3a4b483ca5,

title = "Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment",

abstract = "An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.",

keywords = "CLL-IPI, PFS, chemo-immunotherapy, chronic lymphocytic leukemia, prognosis, progression-free survival",

author = "Massimo Gentile and Shanafelt, {Tait D.} and Mauro, {Francesca Romana} and Gianluigi Reda and Davide Rossi and Luca Laurenti and {Del Principe}, {Maria Ilaria} and Giovanna Cutrona and Ilaria Angeletti and Marta Coscia and Yair Herishanu and Annalisa Chiarenza and Stefano Molica and Stefania Ciolli and Neta Goldschmidt and Francesco Angrilli and Annamaria Giordano and Angela Rago and Osnat Bairey and Giovanni Tripepi and Chaffee, {Kari G.} and Sameer, {Parikh A.} and Ernesto Vigna and Katja Zirlik and Lev Shvidel and Idanna Innocenti and Recchia, {Anna Grazia} and {Di Raimondo}, Francesco and {Del Poeta}, Giovanni and Agostino Cortelezzi and Antonino Neri and Manlio Ferrarini and Gianluca Gaidano and Kay, {Neil E.} and Aaron Polliack and Robin Fo{\`a} and Fortunato Morabito",

year = "2018",

month = nov,

doi = "10.1111/ejh.13149",

language = "English",

volume = "101",

pages = "703--706",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Gentile, M, Shanafelt, TD, Mauro, FR, Reda, G, Rossi, D, Laurenti, L, Del Principe, MI, Cutrona, G, Angeletti, I, Coscia, M, Herishanu, Y, Chiarenza, A, Molica, S, Ciolli, S, Goldschmidt, N, Angrilli, F, Giordano, A, Rago, A, Bairey, O, Tripepi, G, Chaffee, KG, Sameer, PA, Vigna, E, Zirlik, K, Shvidel, L, Innocenti, I, Recchia, AG, Di Raimondo, F, Del Poeta, G, Cortelezzi, A, Neri, A, Ferrarini, M, Gaidano, G, Kay, NE, Polliack, A, Foà, R & Morabito, F 2018, 'Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment', European Journal of Haematology, vol. 101, n. 5, pagg. 703-706. https://doi.org/10.1111/ejh.13149

TY - JOUR

T1 - Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

AU - Gentile, Massimo

AU - Shanafelt, Tait D.

AU - Mauro, Francesca Romana

AU - Reda, Gianluigi

AU - Rossi, Davide

AU - Laurenti, Luca

AU - Del Principe, Maria Ilaria

AU - Cutrona, Giovanna

AU - Angeletti, Ilaria

AU - Coscia, Marta

AU - Herishanu, Yair

AU - Chiarenza, Annalisa

AU - Molica, Stefano

AU - Ciolli, Stefania

AU - Goldschmidt, Neta

AU - Angrilli, Francesco

AU - Giordano, Annamaria

AU - Rago, Angela

AU - Bairey, Osnat

AU - Tripepi, Giovanni

AU - Chaffee, Kari G.

AU - Sameer, Parikh A.

AU - Vigna, Ernesto

AU - Zirlik, Katja

AU - Shvidel, Lev

AU - Innocenti, Idanna

AU - Recchia, Anna Grazia

AU - Di Raimondo, Francesco

AU - Del Poeta, Giovanni

AU - Cortelezzi, Agostino

AU - Neri, Antonino

AU - Ferrarini, Manlio

AU - Gaidano, Gianluca

AU - Kay, Neil E.

AU - Polliack, Aaron

AU - Foà, Robin

AU - Morabito, Fortunato

PY - 2018/11

Y1 - 2018/11

N2 - An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.

AB - An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.

KW - CLL-IPI

KW - PFS

KW - chemo-immunotherapy

KW - chronic lymphocytic leukemia

KW - prognosis

KW - progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85052966783&partnerID=8YFLogxK

U2 - 10.1111/ejh.13149

DO - 10.1111/ejh.13149

M3 - Letter

SN - 0902-4441

VL - 101

SP - 703

EP - 706

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 5

ER -

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo